covalent immunoproteasome inhibitor

subcutaneous agent in Ph. I/II for SLE and LN

designed from proteasome inhibitors

Drug Metabolism and Disposition

Kezar Life Sciences, San Francisco, US

The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616, licensed from Onyx, targets the LMP7 and LMP2 active sites of the immunoproteasome, and is currently in Ph. II trials for autoimmune disorders…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks